Department of Infection and Immunity, Academic Unit of Respiratory Medicine, University of Sheffield, Sheffield, UK.
Thorax. 2012 Aug;67(8):742-6. doi: 10.1136/thoraxjnl-2011-200515. Epub 2011 Jun 22.
Idiopathic pulmonary fibrosis is a progressive lung disease that carries a poor prognosis and for which there are no effective therapies. Although the excessive deposition of extracellular matrix, combined with evidence of recurrent injury to the alveolar epithelium, are well-described there is a pressing need to understand these processes better at a molecular level and thus to identify potential therapeutic targets in this intractable disease. This review considers some recent advances published in Thorax and elsewhere that have improved our understanding of the pathophysiology of idiopathic pulmonary fibrosis, using data both from human cells and tissue and from animal models of pulmonary fibrosis. The studies particularly address the fate of the alveolar epithelial cell and mechanisms of fibrogenesis, and identify mechanistic pathways shared with co-existing conditions such as lung cancer and pulmonary hypertension. The concepts of physiological biomarkers of disease progression and prognosis are also discussed.
特发性肺纤维化是一种进行性肺部疾病,预后不良,目前尚无有效的治疗方法。尽管细胞外基质的过度沉积,加上复发性肺泡上皮损伤的证据,都得到了很好的描述,但人们迫切需要在分子水平上更好地理解这些过程,从而在这种棘手的疾病中确定潜在的治疗靶点。这篇综述考虑了一些最近在《胸科》和其他地方发表的进展,这些进展使用了来自人类细胞和组织以及肺纤维化动物模型的数据,提高了我们对特发性肺纤维化病理生理学的理解。这些研究特别针对肺泡上皮细胞的命运和纤维化机制,并确定了与共存疾病(如肺癌和肺动脉高压)共享的机制途径。还讨论了疾病进展和预后的生理生物标志物的概念。